10 Best Medical Care Facilities Stocks to Buy According to Analysts
This article identifies 10 best medical care facilities stocks based on analyst recommendations. It highlights Option Care Health, Inc. (NASDAQ:OPCH) as one of the top choices, noting its significant upside potential according to analysts. The company's recent ranking on TIME's World's Most Impactful Companies 2026 list and its focus on home and alternate-site infusion care are presented as key indicators of its strong operating model and relevance in the evolving healthcare landscape.
192,894 Shares in Option Care Health, Inc. $OPCH Purchased by Fideuram Intesa Sanpaolo Private Banking S.P.A.
Fideuram Intesa Sanpaolo Private Banking S.P.A. recently acquired a new stake in Option Care Health, purchasing 192,894 shares valued at approximately $5.19 million during the first quarter. This comes as Option Care Health reported Q1 EPS of $0.40, beating analyst expectations, and raised its FY 2026 guidance to 1.820-1.920 EPS. Analyst sentiment remains largely positive, with a "Moderate Buy" consensus and an average price target of $30.54, further supported by recent insider purchases from the CEO and a director.
Louisiana State Employees Retirement System Acquires Shares of 46,000 Option Care Health, Inc. $OPCH
The Louisiana State Employees Retirement System has recently acquired 46,000 shares of Option Care Health, Inc. (NASDAQ:OPCH) valued at approximately $1.238 million in the first quarter. This purchase contributes to the already high institutional ownership of 98.05% in the company. Insiders, including directors Timothy P. Sullivan and Harry M. Jansen Kraemer, Jr., have also increased their holdings, while analysts maintain a "Moderate Buy" rating with a consensus target price of $30.54.
How Investors May Respond To Option Care Health (OPCH) Joining Multiple Russell Value and Small‑Cap Indices
Option Care Health (OPCH) has been added to several Russell value and small-cap indices, including the Russell 2000 Value, increasing its visibility to institutional investors and index-tracking funds. This inclusion, alongside a US$1,000 million share repurchase authorization, may influence market valuation. However, the core investment case still depends on navigating margin pressure, payer dynamics, and therapy mix shifts, despite forecasts projecting significant revenue and earnings growth by 2029.
How Investors May Respond To Option Care Health (OPCH) Joining Multiple Russell Value and Small‑Cap Indices
Option Care Health (OPCH) has been added to several Russell value and small-cap indices, including the Russell 2000 Value, which is expected to increase its visibility among institutional investors and improve trading liquidity. This inclusion, alongside a recent US$1 billion share repurchase authorization, shapes the investment narrative, even as the company navigates margin pressure and therapy mix shifts. The article suggests investors consider these factors in light of the company's projected revenue and earnings growth, which could lead to a significant upside to its current price.
Corient Private Wealth LLC Has $953,000 Stock Position in Option Care Health, Inc. $OPCH
Corient Private Wealth LLC significantly reduced its stake in Option Care Health (OPCH) by 84% in the fourth quarter, holding 29,896 shares valued at $953,000. Despite this reduction, institutional ownership remains high at 98.05%, with several other funds increasing their positions. Option Care Health recently beat EPS estimates with $0.40, and analysts maintain a "Moderate Buy" rating with an average target price of $30.54.
OPCH - Option Care Health Inc Latest SEC Filings
This article provides an overview of Option Care Health Inc. (OPCH) featuring its latest stock performance, key financial metrics, and valuation ratios. It includes detailed information on insider ownership, institutional transactions, profitability, and various technical indicators, alongside a target price and analyst recommendation.
Stephens & Co. initiates coverage of Option Care Health (OPCH) with overweight recommendation
Stephens & Co. has initiated coverage of Option Care Health (OPCH) with an "overweight" recommendation. The firm's analysis likely suggests that Option Care Health's stock is expected to perform better than the average return of the stocks analysts cover. This initiation of coverage by a prominent firm can often influence investor sentiment and lead to increased attention for the company.
Option Care Health, Inc.(NasdaqGS: OPCH) added to Russell 3000 Value Benchmark
Option Care Health, Inc. (NasdaqGS: OPCH), a leading independent provider of home and alternate site infusion services, has been included in the Russell 3000 Value Benchmark. This addition highlights the company's market presence and its comprehensive therapy portfolio spanning various medical conditions. The article also provides recent news, financial data, and analyst ratings for OPCH.
Option Care Health, Inc. (NASDAQ:OPCH) Given Consensus Recommendation of "Moderate Buy" by Analysts
Analysts have given Option Care Health, Inc. (NASDAQ:OPCH) a consensus "Moderate Buy" rating, with an average 12-month price target of $30.54. The company exceeded Q1 earnings estimates, reporting $0.40 per share on $1.35 billion in revenue, and insiders, including the CEO, have recently purchased shares, signaling confidence. Institutional ownership stands at 98.05%.
Option Care Health (OPCH) Short Interest & Short Float | Updated Jun 2026
As of June 15, 2026, Option Care Health (OPCH) had 12.25 million shares sold short, representing a 2.72% decrease from the prior report and 7.93% of the public float. The short interest ratio is 4.1 days to cover, indicating it would take 4.1 days to cover all short positions based on average trading volume. A decrease in short volume suggests bullish sentiment among investors.
Enterprise value to EBITDA forward of Option Care Health, Inc. – NASDAQ:OPCH
The article discusses the enterprise value to EBITDA forward for Option Care Health, Inc. (NASDAQ: OPCH). It appears to be a financial data point available on TradingView, indicating a key financial metric for the company. The rest of the content includes navigation, copyright information, and mentions of various TradingView features and services rather than a detailed analysis of the metric itself.
Option Care Health (OPCH) Stock Could Be 23.1% Undervalued After Weak Revenue And Guidance
Option Care Health (OPCH) recently experienced a pullback due to weaker-than-expected revenue and guidance, attributed to biosimilar pressure. Despite short-term resilience, the stock is down significantly over the past year. Simply Wall St's narrative suggests OPCH is 23.1% undervalued at $21.97 compared to a fair value of $28.58, driven by growth in infusion therapies, but warns of potential challenges from shifting therapy mixes and reimbursement pressures.
Enterprise value to EBIT forward of Option Care Health, Inc. – NASDAQ:OPCH
This article provides financial information for Option Care Health, Inc. (NASDAQ: OPCH), specifically focusing on its enterprise value to EBIT forward. It appears to be a stub or a placeholder page from TradingView, indicating where detailed financial data would be presented. The content mainly consists of navigation and boilerplate information rather than a full analysis.
Option Care Health, Inc. $OPCH Stock Holdings Trimmed by Riverbridge Partners LLC
Riverbridge Partners LLC significantly reduced its stake in Option Care Health (NASDAQ:OPCH) by 22% in the first quarter, selling 278,193 shares. Despite beating EPS estimates, Option Care Health's revenue of $1.35 billion fell short of expectations, though it still represented a 1.3% increase year-over-year. Analyst sentiment remains a "Moderate Buy" with an average price target of $30.54, even as some firms have lowered their targets or ratings.
Option Care Health Inc (OPCH) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Option Care Health Inc (OPCH) as of June 18, 2026. The company currently has a valuation score of 8.29, ranking 46th in the Healthcare Providers & Services industry. Its P/E ratio stands at 17.08, which is significantly below its recent high but slightly above its recent low.
Option Care Health Inc (OPCH) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Option Care Health Inc (OPCH), listing its major individual shareholders and institutional holdings. It provides a breakdown of proportional ownership by investment advisors, hedge funds, banks, and other entities, along with institutional shareholding trends over several quarters. The report also includes recent shareholder activity and the company's inclusion in various ETFs.
UBS Maintains Option Care Health(OPCH.US) With Buy Rating, Maintains Target Price $39
UBS has reiterated its Buy rating for Option Care Health (OPCH.US) and maintained its target price at $39. This indicates a continued positive outlook from the investment bank on the company's stock performance.
Arrowstreet Capital Limited Partnership Acquires 247,118 Shares of Option Care Health, Inc. $OPCH
Arrowstreet Capital Limited Partnership increased its stake in Option Care Health, Inc. by 6.2% in the fourth quarter, acquiring an additional 247,118 shares, bringing its total holding to 4.25 million shares worth $135.4 million. Option Care Health reported quarterly earnings of $0.40 per share, exceeding analyst estimates, and provided FY 2026 EPS guidance. Insider buying activity and a "Moderate Buy" consensus rating from analysts with an average price target of $30.54 were also noted.
Arvin Capital Management LP Reduces Stock Position in Option Care Health, Inc. $OPCH
Arvin Capital Management LP significantly reduced its stake in Option Care Health, Inc. (NASDAQ:OPCH) by 42.0% in the fourth quarter, selling 353,789 shares and now owning 488,572 shares. Despite this, other institutional investors increased their holdings, and company insiders, including Director Timothy P. Sullivan and Director Harry M. Jansen Kraemer, Jr., purchased shares. Analyst ratings for Option Care Health are mixed, with a consensus of "Moderate Buy" and a target price of $30.54, while the company reported earnings per share of $0.40, beating estimates.
Did Conflicting Analyst Views and Druckenmiller’s Endorsement Just Shift Option Care Health's (OPCH) Investment Narrative?
Recent analyst ratings for Option Care Health (OPCH) show conflicting views, with Goldman Sachs initiating a Neutral rating and Bank of America becoming more cautious, despite billionaire Stanley Druckenmiller praising the company. This divergence highlights a tension between the long-term potential of home-based infusion care and immediate challenges like tougher insurance approvals and therapy disruptions. The article suggests that these near-term uncertainties could reshape the company's investment narrative, urging investors to consider both growth prospects and potential risks.
Option Care Health (OPCH) Stock Trades Up, Here Is Why
Option Care Health (OPCH) shares increased by 3.7% after Goldman Sachs initiated coverage with a "Neutral" rating and a $22 price target, despite the stock's recent 33% decline. While this positive news offered a temporary boost, the market views it as a minor change, especially given the company's weak Q1 2026 results and lowered full-year guidance, which led to a 26.4% drop earlier. OPCH is down 35.5% year-to-date and substantially below its 52-week high, indicating ongoing investor concerns.
Option Care Health (NASDAQ:OPCH) Upgraded at The Goldman Sachs Group
The Goldman Sachs Group upgraded Option Care Health (NASDAQ:OPCH) to a "hold" rating. Despite this upgrade, the stock opened lower at $20.08, significantly below its 52-week high, although the company recently surpassed quarterly EPS estimates. Insiders have also made substantial share purchases recently, indicating confidence in the company.
Goldman Sachs initiates Option Care Health stock coverage at neutral
Goldman Sachs initiated coverage on Option Care Health Inc. (NASDAQ:OPCH) with a Neutral rating and a price target of $22.00, noting a balance between long-term growth drivers and near-term earnings uncertainty. The company, the largest independent provider of home and alternate-site infusion services, is facing challenges from biosimilar adoption and formulary shifts despite appearing undervalued. This analysis comes after Option Care Health reported mixed Q1 2026 earnings and appointed a new VP of Investor Relations.
Goldman Sachs initiates Option Care Health stock coverage at neutral
Goldman Sachs initiated coverage on Option Care Health Inc. (NASDAQ:OPCH) with a Neutral rating and a $22.00 price target. The firm acknowledged the company's strong long-term growth drivers in specialty infusion but noted near-term earnings uncertainty due to therapy-specific disruption. Despite a recent 33% stock decline, InvestingPro analysis suggests the stock is undervalued, with the company benefiting from its strategic position in the healthcare services segment.
Geode Capital Management LLC Trims Stock Position in Option Care Health, Inc. $OPCH
Geode Capital Management LLC reduced its stake in Option Care Health, Inc. by 2.0% in the fourth quarter, selling 83,900 shares but still holding over 4.1 million shares valued at approximately $131.2 million. This reduction comes amid recent analyst downgrades, though the consensus remains a "Moderate Buy" with an average target price of $31.25. Despite institutional selling, company insiders, including two directors, have recently purchased shares, with Option Care Health exceeding EPS estimates but missing revenue forecasts in its latest quarterly report.
Option Care Health Appoints Robert Okunski as Vice President, Investor Relations
Option Care Health, Inc. has appointed Robert Okunski as Vice President, Investor Relations, effective May 26, 2026. Okunski will be responsible for leading the company's investor relations strategy, communicating its business strategy and financial performance, and enhancing investor engagement. He brings over two decades of experience in investor relations leadership across various industries.
Option Care Health names Robert Okunski investor relations VP By Investing.com
Option Care Health, Inc. has appointed Robert Okunski as Vice President of Investor Relations, effective May 26. Okunski will be responsible for leading the company's investor relations strategy and communicating with the investment community. He brings over two decades of experience from previous investor relations roles at companies like Enhabit Home Health & Hospice, Velo3D Inc., and SunPower Corporation.
Option Care Health names Robert Okunski investor relations VP By Investing.com
Option Care Health Inc. has appointed Robert Okunski as its new Vice President of Investor Relations, effective May 26. Okunski will be responsible for leading the company's investor relations strategy and communicating its business strategy, financial performance, and growth opportunities to the investment community. He brings over two decades of experience in investor relations from various industries, including healthcare and technology.
Option Care Health Appoints Robert Okunski As Vice President, Investor Relations
Option Care Health has announced the appointment of Robert Okunski as its new Vice President, Investor Relations. This brief news item confirms the change in leadership for the company's investor relations department.
Option Care Health Appoints Robert Okunski as Vice President, Investor Relations
Option Care Health, Inc., the largest independent provider of home and alternate site infusion services, has appointed Robert Okunski as Vice President, Investor Relations, effective May 26, 2026. Okunski will be responsible for leading the company's investor relations strategy, communicating its business strategy, financial performance, and growth opportunities to the investment community. He brings over two decades of experience in investor relations leadership across healthcare, technology, and energy industries.
20+ year investor relations leader Robert Okunski joins Option Care Health
Option Care Health (NASDAQ: OPCH) has appointed Robert (Bob) Okunski as Vice President, Investor Relations, effective May 26, 2026. Okunski will be responsible for leading the company's investor relations strategy, serving as the primary liaison with the investment community, and communicating business strategy and financial performance. He brings over two decades of experience from previous senior roles at Enhabit Home Health & Hospice, Velo3D, SunPower, Spansion, and PeopleSoft.
Option Care Health Appoints Robert Okunski as Vice President, Investor Relations
Option Care Health, Inc. has appointed Robert Okunski as Vice President, Investor Relations, effective May 26, 2026. Okunski will be responsible for leading the company's investor relations strategy and communicating its financial performance and growth opportunities to the investment community. He brings over two decades of experience in investor relations leadership across various industries.
Option Care Health Appoints Robert Okunski as Vice President, Investor Relations
Option Care Health, Inc. has announced the appointment of Robert Okunski as Vice President, Investor Relations, effective May 26, 2026. Okunski will be responsible for leading the company's investor relations strategy, communicating business strategy, financial performance, and growth opportunities to stakeholders. He brings over two decades of experience in investor relations across multiple industries.
Option Care Health (NasdaqGS:OPCH) Stock Forecast & Analyst Predictions
Option Care Health (OPCH) is forecast to grow earnings and revenue by 11.5% and 6.3% per annum, respectively, with EPS projected to grow by 12% annually. Despite these growth forecasts, the stock experienced a significant drop after Q1 2026 results missed expectations and guidance was cut, leading to multiple investigations into potential securities fraud. The company's future performance is being closely watched, particularly regarding the impact of the Stelara biosimilar conversion and the outcomes of ongoing legal reviews.
Option Care Health, Inc. (NASDAQ:OPCH) Given Average Rating of "Moderate Buy" by Analysts
Option Care Health, Inc. (NASDAQ:OPCH) has received an average rating of "Moderate Buy" from analysts, with a consensus 12-month price target of $31.25. The company recently exceeded earnings estimates for its latest quarter, reporting $0.40 EPS against a $0.37 consensus, despite revenue of $1.35 billion being slightly below expectations. Insider buying has been noted, including significant purchases by two directors in May, while institutional investors maintain a majority stake in the company.
Option Care Health Awarded TIME's World's Most Impactful Companies 2026 Ranking
Option Care Health has been recognized as No. 15 on TIME's World’s Most Impactful Companies 2026 list, a global acknowledgment for organizations delivering significant positive impact. This ranking, presented by TIME and Statista, is based on a rigorous, science-based methodology from The Upright Project, assessing net-positive contributions across Society, Knowledge, Health, and Environment. The company's President and CEO, John C. Rademacher, emphasized that this recognition underscores their commitment to providing extraordinary care that changes lives and creates value for both shareholders and society.
Option Care Health Ranked No. 15 on TIME's World’s Most Impactful Companies 2026 List
Option Care Health has been recognized as No. 15 on TIME's World’s Most Impactful Companies 2026 list, a prestigious global acknowledgment of organizations making significant positive contributions to society, the environment, and the economy. The ranking, determined by the Upright Project’s Net Impact Model, highlights Option Care Health's commitment to responsible business practices and its role as the largest independent provider of home and alternate site infusion services in the U.S. CEO John C. Rademacher expressed pride in the achievement, emphasizing the team's dedication to transforming healthcare and impacting patients' lives.
Largest U.S. independent home-infusion provider earns No.15 on TIME impact list
Option Care Health (NASDAQ:OPCH), the largest independent provider of home and alternate site infusion services in the U.S., has been ranked No. 15 on TIME and Statista's World’s Most Impactful Companies 2026 list. This recognition, based on The Upright Project’s science-based Net Impact Model, highlights the company's significant positive contributions across Society, Knowledge, Health, and Environment. With over 8,000 team members serving patients in all 50 states, Option Care Health's CEO, John C. Rademacher, expressed pride in the team's impact on changing lives.
Option Care Health, Inc. (OPCH) Stock Analysis: Unveiling A 39.83% Upside Potential
Option Care Health, Inc. (OPCH) is a significant player in the healthcare sector, specializing in home and alternate site infusion services, with a market cap of $3.28 billion. Despite a recent stock dip, analysts are bullish with a 39.83% potential upside, and the company focuses on growth and expansion over immediate shareholder dividends. Investors should consider the strong foundation and promising projections against current bearish technical indicators.
Option Care Health (Nasdaq:OPCH) - Stock Analysis
This Simply Wall St analysis provides a detailed overview of Option Care Health (OPCH), highlighting its current valuation, growth prospects, and recent financial performance. The company is trading 18.2% below its estimated fair value, with analysts forecasting 11.47% annual earnings growth, though it carries a high level of debt. Recent news indicates legal probes due to a Q1 2026 revenue miss and reduced full-year guidance, which has caused a significant stock price drop and downward revisions to analyst price targets.
Jupiter Asset Management Ltd. Boosts Stock Position in Option Care Health, Inc. $OPCH
Jupiter Asset Management Ltd. significantly increased its stake in Option Care Health, Inc. (NASDAQ:OPCH) by 35.3% in the fourth quarter of the previous year, now holding 708,742 shares valued at approximately $22.6 million. Insider activity also shows recent purchases by CEO John Charles Rademacher and Director Timothy P. Sullivan, with a total of 73,264 shares bought by insiders over the last 90 days. While analysts offer a mixed but largely positive outlook, with a "Moderate Buy" consensus and an average price target of $31.25, some firms have adjusted their targets or ratings.
OPCH - Option Care Health Inc Stock Price and Quote
This article provides comprehensive financial data, news, and analyst ratings for Option Care Health Inc. (OPCH). It includes stock performance metrics, insider trading activities, and a summary of recent earnings reports and company announcements, detailing its services in home and alternate site infusion therapy.
Swedbank AB Decreases Position in Option Care Health, Inc. $OPCH
Swedbank AB reduced its stake in Option Care Health, Inc. (NASDAQ:OPCH) by 3.1% in the fourth quarter, selling 55,532 shares and owning 1.73 million shares valued at $54.99 million. The article also notes recent insider purchases by a director and CEO, totaling over $760,000, and provides an overview of recent analyst ratings and the company's financial performance.
Option Care Health (OPCH) director receives $200,000 restricted stock grant
Pate R. Carter, a director at Option Care Health, Inc. (OPCH), was granted 8,997 restricted stock units (RSUs) valued at $200,000. These RSUs were awarded on May 20, 2026, and are set to vest in full on May 20, 2027, bringing his direct holdings to 20,620 shares. This transaction, reported via a Form 4 filing, is a compensation-related acquisition rather than an open-market purchase.
Director at Option Care Health (NASDAQ: OPCH) receives $200K RSU grant
Option Care Health director Elizabeth D. Bierbower was granted 8,997 restricted stock units (RSUs) valued at $200,000, based on the closing price on May 20, 2026. These RSUs will fully vest on May 20, 2027, increasing her direct holdings to 32,871 shares. This transaction is classified as a compensation grant rather than an open-market purchase, aligning her incentives with the company's performance.
Option Care Health (OPCH) director granted 13,833 RSUs as fees and $200K award
Option Care Health director Timothy P. Sullivan received two stock awards on May 20, 2026. He was granted 4,836 restricted stock units as part of a $200,000 award and 8,997 restricted stock units in lieu of cash retainer fees, totaling 13,833 RSUs, all based on the closing share price of $22.23. These units are classified as routine equity-based director compensation and are set to vest in full on May 20, 2027.
OPCH Technical Analysis | Trend, Signals & Chart Patterns | OPTION CARE HEALTH INC (NASDAQ:OPCH)
This article provides a technical analysis of OPTION CARE HEALTH INC (OPCH), assigning it a poor technical rating of 0 out of 10. Both long and short-term trends are negative, and the stock is underperforming the overall market and its industry peers. Key areas of concern include high volatility, a wide trading range, and negative signals from multiple moving averages.
Option Care Health (OPCH) holders back board, auditor and pay at 2026 meeting
Option Care Health, Inc. (OPCH) stockholders approved all proposals at their 2026 Annual Meeting. This included the election of nine director nominees, the ratification of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2026, and the non-binding advisory approval of executive officer compensation. All proposals received significant majority support from the voting stockholders.
Director at Option Care Health (OPCH) receives 8,997 RSUs worth $200,000
Option Care Health director Norman L. Wright was granted 8,997 restricted stock units (RSUs) on May 20, 2026, valued at $200,000 based on that day's closing share price. These RSUs will fully vest on May 20, 2027, provided he remains eligible through that date. Following this equity award, Wright directly holds 24,498 shares of the company's common stock.
